Aloxi® (palonosetron hydrochloride) Injection is a potent, highly selective 5-HT3 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). Approved by the U.S. Food and Drug Administration (FDA) on July 25, 2003 and commercially launched in September 2003, Aloxi is the first and only 5-HT3 receptor antagonist to be indicated for the prevention of both acute and delayed CINV caused by moderately emetogenic chemotherapy.
To maximize the value of the Aloxi franchise Helsinn Healthcare, is conducting a phase 3 program to evaluate the safety and efficacy of Aloxi for the prevention of postoperative nausea and vomiting (PONV).
About Postoperative Nausea and Vomiting
PONV is a common consequence of anesthetic and surgical procedures. It is estimated approximately 25%-30% of patients undergoing anesthesia and surgical procedures will be affected by PONV. PONV is most frequently experienced by patients who undergo gynecological, abdominal, ear, nose and throat surgeries. If not prevented, PONV can result in longer hospital stays, increased hospital admissions and higher healthcare costs. If approved for the prevention of PONV, Aloxi injection would compete in a market currently estimated to exceed $400 million annually in the United States.
Patients and health care providers seeking information regarding clinical trials may call MGI PHARMA toll-free at 1-800-562-5580 and press 1 to access our Medical Communications Help Line.